Ownership signal CIK-linked ownership evidence from parsed SEC filings. 2 signals
Large-stake signal

Form

SCHEDULE 13D/A

Active or control-oriented beneficial ownership filing.

Ownership

9.9%

Beneficial ownership of this reported class.

Shares

1,670,081 shares

Shares beneficially owned as disclosed.

Event date

13 Nov 2025

Date tied to the ownership event or amendment.

Accepted by SEC

17 Nov 2025

EDGAR acceptance date.

How to read this large-stake filing
  • Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
  • Compare this filing with the holder history and issuer page before treating the percentage as a current position.
  • Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
Subject security Names, identifiers, and filing context for this profile. 2 source fields
Symbol
MRKR
Shares outstanding
16,869,505 shares
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
SCHEDULE 13D/A
Accepted by SEC
17 Nov 2025, 16:22:54 UTC
Event date
13 Nov 2025
Prior SEC filing
18 Aug 2025
Source filing
View source filing

Key filing fact

New Enterprise Associates 16, L.P. disclosed 9.9% ownership in Marker Therapeutics, Inc. Common Stock, par value $0.001 per share (MRKR) on 13 Nov 2025.

Key facts

  • New Enterprise Associates 16, L.P. filed SCHEDULE 13D/A for Marker Therapeutics, Inc. Common Stock, par value $0.001 per share (MRKR).
  • Disclosed ownership: 9.9%.
  • Date of event: 13 Nov 2025.

Change

  • Previous schedule filing date: 18 Aug 2025.
  • Current filing was accepted on 17 Nov 2025, 16:22.

Research use

  • This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
  • Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.

Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

View source filing

Reporting persons

Disclosed reporting parties (10)

Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.

Name Ownership Shares owned Sole voting power Shared voting power Signature Title CIK
New Enterprise Associates 16, L.P. 9.9% 1,670,081 0 1,670,081 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer 0001694560
NEA Partners 16, L.P. 9.9% 1,670,081 0 1,670,081 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer 0001712881
NEA 16 GP, LLC 9.9% 1,670,081 0 1,670,081 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Anthony A. Florence Jr., Managing Partner and Co-Chief Executive Officer 0001712882
Forest Baskett 9.9% 1,670,081 0 1,670,081 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Forest Baskett 0001277631
Ali Behbahani 9.9% 1,670,081 0 1,670,081 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Ali Behbahani 0001613867
Carmen Chang 9.9% 1,670,081 0 1,670,081 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Carmen Chang 0001746342
Anthony A. Florence, Jr. 9.9% 1,670,081 0 1,670,081 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr. 0001559827
Mohamad H. Makhzoumi 9.9% 1,670,081 0 1,670,081 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Mohamad H. Makhzoumi 0001630226
Scott D. Sandell 9.9% 1,670,081 0 1,670,081 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Scott D. Sandell 0001237289
Paul Walker 9.9% 1,670,081 0 1,670,081 /s/ Zachary Bambach Zachary Bambach as attorney-in-fact for Paul Walker 0001553150
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .